Matthew J Goldseth

10 Dividend Stocks for Enterprising Investors

I would argue one point here....To put Merck and Pfizer in the same boat shows a lack of insight bthat screeners and quick reviews of financials wont provide. Illustrating only a lack of growth and pointing out dividends as a balancing factor overlooks the greater acquisition strategy of these firms. Merck's acquisition of Schering definitely provides a boost and makes it, I believe,the #2 drugmaker and gives it greater leverage for future deals, pricing, R&D, etc.This is a great investment as opposed to PFE which not only LACKED growth but was facing numerous patent expirations and lacking any suitable strategy to counter that, they slashed the dividend to preserve capital.

I dare say that hose of us who bought MRK in the last few weeks are feeling a lot more secure in the future than PFE shareholders!